Treatment with epidermal growth factor receptor inhibitor erlotinib combined with cisplatin-based chemoradiation seems safe and effective for locally advanced cervical cancer, according to a study.
Adjuvant bevacizumab increases overall survival in cervical cancer, and two studies show benefits of bevacizumab on PFS in newly diagnosed glioblastoma as well.
A phase 2 trial of bevacizumab in addition to cisplatin and pelvic radiation for locally advanced cervical cancer found that adding bevacizumab to the existing standard of care showed promising overall results.
The heat profile from a person's blood, known as a plasma thermogram, can serve as an indicator for the presence or absence of cervical cancer, including the stage of the cancer.
Researchers from Boston, Massachusetts; Mexico; and Norway have completed a comprehensive genomic analysis of cervical cancer in two patient populations.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|